Unless otherwise noted, speakers have nothing to disclose.

Moderators

Robert Merritt, MD
Disclosure: Astra Zeneca: Advisory Board (Ongoing); Intuitive Surgical: Speaker (Ongoing)

Jason Long, MD, MPH
Disclosure: DaVinci Intuitive Surgical: Consultant (Ongoing); Medscape: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Stryker: Consultant (Ongoing)

Presentations

1. Pathologic Downstaging Following Neoadjuvant Chemoimmunotherapy for Locally Advanced Lung Cancer is Associated with Survival Comparable to Early Stage-Matched Disease
   Charles D. Logan, MD
    
2. Nomogram to Predict Adjuvant Chemotherapy Benefit in Stage 1B/2A Lung Cancer
   Kayla Rizzo, DO
    
3. Afatinib as Neoadjuvant Treatment of Stage III EGFR-Mutant Non-Small Cell Lung Cancer (TEAM-LungMate 004): A Prospective, Single-Arm, Phase II Study
   Dongliang Bian
    
4. Summary of key trials on perioperative immunotherapy and Targeted Molecular Therapy in NSCLC
   David R. Jones, MD
   Disclosure: AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Merck & Co.: Advisory Board (Ongoing)
    
5. Expert Panel/Q&A
   David R. Jones, MD
   Disclosure: AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Merck & Co.: Advisory Board (Ongoing)
   
   Jessica S. Donington, MD
   Disclosure: AstraZeneca; BMS; Merck; Roche/Genentech: Advisory Board (Ongoing), Speaker (Ongoing)
   
   Nathaniel R. Evans, III, MD
   Disclosure: Bristol Myers Squibb: Advisory Board (Ongoing); Bristol Myers Squibb Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Intuitive Surgical: Consultant (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing)